Malachite Innovations, Inc. (MLCT) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Malachite Innovations, Inc. (MLCT) trades at $0.195. Malachite Innovations, Inc. focuses on health and wellness products, including novel cannabosides and a THC-glycoside prodrug. The company also invests in eco-friendly technological innovations. Market cap: $17.5M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for MLCT: MLCT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MLCT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MLCT: 2/3 scored disciplines lean bullish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Malachite Innovations, Inc. (MLCT) Healthcare & Pipeline Overview
Malachite Innovations, Inc. develops and markets health and wellness products, including novel cannabosides and a THC-glycoside prodrug (VBX-100) targeting gastrointestinal diseases. The company also invests in eco-friendly tech, positioning itself in the evolving biotechnology and environmental solutions sectors.
What Is the Investment Thesis for MLCT?
Malachite Innovations presents a speculative investment opportunity within the biotechnology and environmental solutions sectors. The company's focus on novel cannabosides and the development of VBX-100 for gastrointestinal diseases could provide significant upside potential if clinical trials are successful and regulatory approvals are obtained. The company's P/E ratio is 2.8 and profit margin is 35.7%. However, the company's OTC listing and negative gross margin of -1.2% indicate substantial risks. Successful commercialization of VBX-100 and strategic investments in environmental technologies are key catalysts. The company's high beta of 2.11 suggests high volatility.
Based on FMP financials and quantitative analysis
MLCT Key Highlights
Market capitalization of $17.5M indicates a micro-cap company with potential for high growth but also significant risk.
- P/E ratio of 2.8 suggests the company is potentially undervalued compared to its earnings, but this should be viewed cautiously given the negative gross margin.
- Profit margin of 35.7% indicates strong profitability on the revenue generated, but this is offset by the negative gross margin, suggesting high cost of goods sold.
- Beta of 2.11 indicates the stock is significantly more volatile than the market, implying higher risk and potential for larger price swings.
- The company has no dividend yield, which is typical for growth-oriented biotechnology companies that reinvest earnings into research and development.
Who Are MLCT's Competitors?
MLCT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMHV American Hemp Ventures, Inc. | $0.98 | +0.00% | $16.5M | 46 |
| CRPOF Ceapro Inc. | $0.17 | -13.04% | $13.3M | 46 |
| KMSTF Kadimastem Ltd | $3.21 | -3.02% | $9.50M | 44 |
| NOXOF Noxopharm Limited | $0.04 | +0.00% | $14.8M | 43 |
| OCEL Organicell Regenerative Medicine, Inc. | $2.74 | -0.27% | $20.0M | 49 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MLCT's Key Strengths?
Portfolio of approximately 100 novel cannabosides.
- Development of VBX-100 for gastrointestinal diseases.
- Investment in environmental technology innovations.
- Relatively high profit margin (35.7%).
What Are MLCT's Weaknesses?
Negative gross margin (-1.2%).
- OTC listing indicates higher risk and lower liquidity.
- Limited information available on specific products and technologies.
- Small market capitalization ($0.02 billion) makes it vulnerable.
What Could Drive MLCT Stock Higher?
Clinical trial results for VBX-100 in treating gastrointestinal diseases.
- Regulatory approvals for new cannabinoid-based products.
- Strategic investments in promising environmental technology companies.
- Expansion of the company's portfolio of novel cannabosides.
- Partnerships and collaborations with other companies in the biotechnology and environmental sectors.
What Are the Key Risks for MLCT?
Financial-distress signal — its Altman Z-Score of -0.38 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory uncertainty surrounding cannabinoid-based products.
- Competition from established pharmaceutical companies and other biotech firms.
- Risk of clinical trial failures for VBX-100.
- Negative gross margin indicates cost management challenges.
- OTC listing indicates higher risk and lower liquidity.
What Are the Growth Opportunities for MLCT?
- Expansion of Cannabinoid Product Line: The market for cannabinoid-based health and wellness products is growing, driven by increasing consumer acceptance and ongoing research into therapeutic applications. Malachite Innovations can capitalize on this trend by expanding its portfolio of novel cannabosides and developing new formulations targeting specific health conditions.
- Clinical Development of VBX-100: The successful clinical development and regulatory approval of VBX-100 for the treatment of gastrointestinal diseases, such as IBD and IBS, represents a significant growth catalyst. These conditions affect a large patient population, and there is a need for more effective and targeted therapies. Positive clinical trial results and subsequent commercialization could generate substantial revenue streams for Malachite Innovations.
- Strategic Investments in Environmental Technologies: Malachite Innovations' strategy of identifying, investing in, and repositioning environmental situations offers growth opportunities in the expanding environmental solutions sector. By focusing on technological innovations and eco-friendly solutions, the company can capitalize on increasing environmental awareness and regulatory pressures. The market for environmental technologies is projected to grow significantly in the coming years, driven by investments in renewable energy, waste management, and pollution control.
- Partnerships and Collaborations: Forming strategic partnerships and collaborations with other companies in the biotechnology and environmental sectors can accelerate Malachite Innovations' growth. Collaborations can provide access to new technologies, markets, and expertise, as well as share the costs and risks associated with research and development. Potential partners include pharmaceutical companies, research institutions, and environmental technology firms.
- Geographic Expansion: Expanding into new geographic markets, both domestically and internationally, can drive revenue growth for Malachite Innovations. The company can target regions with favorable regulatory environments for cannabinoid-based products and strong demand for environmental solutions. International expansion may require partnerships with local distributors and compliance with local regulations.
What Are MLCT's Competitive Advantages?
- Proprietary portfolio of approximately 100 novel cannabosides.
- Patent protection for THC-glycoside (VBX-100) and related technologies (if patents are granted).
- Expertise in developing and formulating cannabinoid-based products.
- Early-stage investments in promising environmental technologies.
What Does MLCT Do?
Malachite Innovations, Inc., established in 2007 and headquartered in Cleveland, Ohio, operates in the health and wellness sector, providing a range of products in the United States. Formerly known as Vitality Biopharma, Inc., the company rebranded in October 2021 to reflect its broader focus. Malachite Innovations offers a portfolio of approximately 100 novel cannabosides, including glycosylated tetrahydrocannabinol, cannabidiol, cannabidivarin, and cannabinol. A key product under development is THC-glycoside (VBX-100), an oral prodrug designed for the treatment of gastrointestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Beyond its core biopharmaceutical activities, Malachite Innovations also identifies, invests in, and repositions environmental situations, emphasizing technological innovations and eco-friendly solutions. This diversification aims to capitalize on emerging opportunities in the environmental sector, complementing its health and wellness product offerings.
What Products and Services Does MLCT Offer?
- Develops and markets health and wellness products.
- Offers a portfolio of approximately 100 novel cannabosides.
- Develops THC-glycoside (VBX-100) as an oral prodrug.
- Targets gastrointestinal diseases like IBD and IBS with VBX-100.
- Identifies and invests in environmental technology innovations.
- Focuses on eco-friendly solutions.
How Does MLCT Make Money?
- Develops and patents novel cannabosides and related products.
- Outlicenses or directly sells its health and wellness products.
- Invests in and repositions environmental technology companies.
- Generates revenue through product sales and licensing agreements.
What Industry Does MLCT Operate In?
Malachite Innovations operates in the biotechnology and health & wellness sectors, which are characterized by rapid innovation and evolving regulatory landscapes. The market for cannabosides and cannabinoid-based therapies is expanding, driven by increasing acceptance of medical cannabis and ongoing research into therapeutic applications. The company also participates in the environmental solutions sector, which is experiencing growth due to increasing environmental awareness and regulatory pressures. Competition includes both established pharmaceutical companies and emerging biotech firms, as well as companies focused on environmental technologies.
Who Are MLCT's Key Customers?
- Patients suffering from gastrointestinal diseases (potential VBX-100 users).
- Consumers seeking health and wellness products containing cannabosides.
- Environmental technology companies seeking investment and repositioning.
- Pharmaceutical companies interested in licensing novel drug candidates.
Insider Activity
The most recent 12 insider filings for Malachite Innovations, Inc. break down as 1 sales and 11 purchases. On net that is roughly 8.1M shares disposed (about $585K), a signal worth weighing alongside the fundamentals.
Financial Health
Malachite Innovations, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.38 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Malachite Innovations, Inc. stands at 91.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 10.0%, showing how much profit it generates from its asset base. MLCT trades at a trailing price-to-earnings ratio of 2.76, below the Healthcare sector average of ~23x. Its free cash flow yield is -0.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.57 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 22.5%, the inverse of the P/E and a quick read on earnings relative to price.
Malachite Innovations, Inc. (MLCT) Valuation Context
Valued at $17.5M, MLCT is classified as a micro-cap stock.
Company Profile
Malachite Innovations, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cleveland, US. The company is led by CEO Michael R. Cavanaugh CPA,. MLCT has traded publicly since 2012.
MLCT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Portfolio of approximately 100 novel cannabosides.
- Development of VBX-100 for gastrointestinal diseases.
- Investment in environmental technology innovations.
- Relatively high profit margin (35.7%).
Bear Case
- Negative gross margin (-1.2%).
- OTC listing indicates higher risk and lower liquidity.
- Limited information available on specific products and technologies.
- Small market capitalization ($0.02 billion) makes it vulnerable.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
MLCT Latest News
No recent news available for MLCT.
MLCT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MLCT.
Price Targets
Wall Street price target analysis for MLCT.
MLCT MoonshotScore
What does this score mean?
The MoonshotScore rates MLCT 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Michael R. Cavanaugh CPA,
CEO
Michael R. Cavanaugh is a Certified Public Accountant (CPA) and serves as the CEO of Malachite Innovations, Inc. His background likely includes experience in financial management, accounting, and strategic leadership. As a CPA, he brings expertise in financial reporting, compliance, and risk management to the company. His prior roles and experiences are not specified in the provided data.
Track Record: Information on Michael R. Cavanaugh's specific achievements and strategic decisions at Malachite Innovations is not available in the provided data. Therefore, it is not possible to assess his track record or identify key milestones achieved under his leadership. His role involves managing 74 employees.
MLCT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Malachite Innovations may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. Unlike NYSE or NASDAQ listings, OTC Other stocks often lack stringent listing requirements, resulting in increased risk and potential for speculative trading.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in MLCT.
- Low liquidity can make it difficult to buy or sell shares.
- Potential for price manipulation due to low trading volume.
- OTC Other status indicates the company may not meet minimum financial standards.
- Higher risk of delisting or trading suspension.
- Verify the company's financial statements and SEC filings (if available).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Monitor trading volume and price activity for signs of manipulation.
- Consult with a qualified financial advisor before investing.
- The company has been in operation since 2007.
- Focus on developing innovative cannabosides and environmental technologies.
- Presence of a CPA as CEO suggests financial oversight.
- Relatively high profit margin (35.7%) if accurate.
Common Questions About MLCT (Healthcare)
What does Malachite Innovations, Inc. do?
Malachite Innovations, Inc. operates in the health and wellness sector, focusing on the development and marketing of novel cannabosides and related products. The company's key product under development is THC-glycoside (VBX-100), an oral prodrug targeting gastrointestinal diseases like IBD and IBS.
What do analysts say about MLCT stock?
As of March 18, 2026, there is no readily available analyst coverage or consensus on Malachite Innovations (MLCT) stock, likely due to its OTC listing and small market capitalization. Key valuation metrics include a market cap of $17.5M, a P/E ratio of 2.8, and a profit margin of 35.7%.
What are the main risks for MLCT?
Malachite Innovations faces several key risks, including regulatory uncertainty surrounding cannabinoid-based products, competition from established pharmaceutical companies, and the potential for clinical trial failures for VBX-100. The company's negative gross margin indicates challenges in managing production costs. Additionally, its OTC listing implies higher risk and lower liquidity compared to stocks listed on major exchanges. Investors should carefully consider these risks before investing in MLCT.
What are the key factors to evaluate for MLCT?
Evaluate MLCT on fundamentals, analyst consensus, and risk factors. P/E: 2.8x vs the S&P 500's ~20-25x. Malachite Innovations presents a speculative investment opportunity within the biotechnology and environmental solutions sectors. Not financial advice.
How frequently does MLCT data refresh on this page?
MLCT's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MLCT's recent stock price performance?
Malachite Innovations, Inc. (MLCT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Portfolio of approximately 100 novel cannabosides. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MLCT overvalued or undervalued right now?
Malachite Innovations, Inc. (MLCT) trades at 2.8x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MLCT before investing?
Before investing in Malachite Innovations, Inc. (MLCT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's specific products and technologies.
- OTC listing indicates higher risk and lower liquidity.
- Financial data may not be as reliable as for companies listed on major exchanges.